2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

	For the six months ended June 30, 2020	2019
	(RMB'000)	*(RMB'000)*
	(Unaudited)	*([illegible])*
[illegible]	**465,150**	378,910
[illegible]	**39,404**	52,661
[illegible]	**(10,503)**	(7,120)
[illegible]	**28,901**	45,541
[illegible] C[illegible]	**36,410**	52,064
[illegible]	**(7,509)**	(6,523)

	As at June 30, 2020	A[illegible] D[illegible] 31, 2019
	(RMB'000)	*(RMB'000)*
	(Unaudited)	*(A[illegible])*
[illegible]	**2,274,908**	2,117,352
[illegible]	**960,485**	855,843
[illegible]	**1,314,423**	1,261,509
E[illegible] C[illegible]	**1,186,459**	1,164,484
[illegible]	**127,964**	97,025

[illegible]

4 MANAGEMENT DISCUSSION AND ANALYSIS

4.1 Financial Review

[illegible] RMB465.2 [illegible] 22.8% [illegible] 2019. [illegible] RMB438.9 [illegible] 21.8% [illegible] 2019. [illegible] 26.3% ([illegible] 30, 2019: 22.3%). [illegible] RMB128.3 [illegible] 39.4% [illegible] 2019. [illegible] RMB36.4 [illegible] 30.1% [illegible] 2019, [illegible] RMB26.2 [illegible] 2019, [illegible] RMB13.3 [illegible] RMB4.8 [illegible] 2019 [illegible] 109.9%.

4.1.1 Revenue and Cost of Revenue

[illegible]

[illegible]:

	For the six months ended June 30,	
	2020	2019
	(RMB'000)	*(RMB'000)*
	(Unaudited)	[illegible]
[illegible]	**438,886**	360,210
[illegible]	**19,116**	15,281
[illegible]	**7,148**	3,419
Total revenue	**465,150**	378,910

[illegible]

[illegible]:

	For the six months ended June 30, 2020 (RMB'000) (Unaudited)	2019 ([illegible]B'000) ([illegible])
Treatment and general healthcare services		
[illegible]	**337,751**	263,580
C[illegible]	**237,419**	197,304
[illegible]	**100,332**	66,276
Pharmaceutical sales		
[illegible]	**101,135**	96,630
C[illegible]	**86,044**	82,629
[illegible]	**15,091**	14,001
Owned hospitals		
[illegible]	**438,886**	360,210
C[illegible]	**323,463**	279,933
[illegible]	**115,423**	80,277

D[illegible] [illegible]B438.9 [illegible] [illegible]B78.7 [illegible] 2019, [illegible] C [illegible] C [illegible] C [illegible] 2019. D[illegible] 43.8% [illegible] 2019, [illegible].

[illegible]

	For the six months ended June 30, 2020 (Unaudited)	2019 [illegible]
Inpatients		
[illegible]	**6,853**	5,593
E[illegible]	**1,240,393**	1,012,333
[illegible] *(%)*	**83.1**	84.9
[illegible]	**1,030,392**	859,061
[illegible] *([illegible]B'000)*	**324,990**	251,945
A[illegible] *([illegible]B)*	**315**	293
[illegible] *([illegible]B'000)*	**53,841**	50,926
A[illegible] *([illegible]B)*	**52**	59
Total inpatient revenue *(RMB'000)*	**378,831**	302,871
Total average inpatient spending per bed-day *(RMB)*	**368**	353
Outpatients		
[illegible]	**125,852**	105,986
[illegible] *([illegible]B'000)*	**12,761**	11,635
A[illegible] *([illegible]B)*	**101**	110
[illegible] *([illegible]B'000)*	**47,294**	45,704
A[illegible] *([illegible]B)*	**376**	431
Total outpatient revenue *(RMB'000)*	**60,055**	57,339
Total average outpatient spending per visit *(RMB)*	**477**	541
Total treatment and general healthcare services revenue *(RMB'000)*	**337,751**	263,580
Total pharmaceutical sales revenue *(RMB'000)*	**101,135**	96,630

D... B378.8 ..., ... 25.1% ... 2019, ... (.) ... 19.9% ... C ... C ... (.) ... 4.2%. ... 86.3% (... 30, 2019: 84.1%).

D... B60.1 ..., ... 4.7% ... 2019, ... 18.7%. ... 13.7% (... 30, 2019: 15.9%).

D... 28.1% ... 2019, ... 77.0% ... (... 30, 2019: 73.2%); ... 4.7% ... 2019, ... 23.0% ... (... 30, 2019: 26.8%), ... : ... 14.2% (... 30, 2019: 16.8%), ... 78.8% (... 30, 2019: 79.7%).

C... k ... :

	For the six months ended June 30,	
	2020	2019
	(RMB'000)	*(...B'000)*
	(Unaudited)	*(...)*
...	**112,156**	101,813
E...	**110,048**	91,091
D...	**15,297**	14,119
D...	**37,019**	30,236
C...	**18,390**	16,577
...	**11,647**	7,807
...	**18,906**	18,290
Cost of revenue of owned hospitals	**323,463**	279,933

D ,

B323.5 , 15.6%

2019,

: ( )

, 28.1%

2019; ( )

; ( )

.

F , 34.7% (

30, 2019: 36.4%).

34.0% (30,

2019: 32.5%).

16.2% (30, 2019: 15.8%).

, . D

,

B19.1 ,

B11.3 (30, 2019: B12.8);

B5.8 (

30, 2019:).

,

, . D ,

B7.1 (30, 2019: B3.4

),

B3.9 .

4.1.2 Gross Profit and Gross Profit Margin

D , B128.3 , 39.4% 2019. B115.4 , 43.8% 2019. k :

	For the six months ended June 30,	
	2020	2019
	(Unaudited)	( )
	29.7%	25.1%
	14.9%	14.5%
	26.3%	22.3%
	47.1%	62.8%
Consolidated gross profit margin	**27.6%**	24.3%

D , 27.6% (30, 2019: 24.3%), 4.6 2019, - .

4.1.3 Tax and Surcharge

D , B2.0 (30, 2019: B0.8).

4.1.4 Selling Expenses

D , B3.7 (30, 2019: B4.5), B0.8 2019. 0.8% ’ (30, 2019: 1.2%).

4.1.5 Administrative Expenses

D [illegible] k [illegible] :

	For the six months ended June 30,	
	2020	2019
	(RMB'000)	*(RMB'000)*
	(Unaudited)	[illegible]
E [illegible]	**35,136**	33,962
D [illegible]	**5,970**	5,709
C [illegible]	**2,406**	3,976
[illegible]	**1,468**	2,188
[illegible]	**9,659**	7,055
Total administrative expenses	**54,639**	52,890

D [illegible] B54.6 [illegible], [illegible] 3.3% [illegible] 2019, [illegible] 3.5% [illegible]. D [illegible], [illegible] 12.4% ([illegible] 30, 2019: 14.7%).

4.1.6 Research and Development Expenses

D [illegible], [illegible] B2.6 [illegible] ([illegible] 30, 2019: B2.3 [illegible]), [illegible] 14.5% [illegible] 2019. [illegible] 0.6% ([illegible] 30, 2019: 0.6%).

4.1.7 Finance Expenses – Net

	For the six months ended June 30,	
	2020	2019
	(RMB'000)	*(B'000)*
	(Unaudited)	*( )*
	2,454	1,925
F /( )	**125**	(759)
B	**(9,165)**	(3,520)
	(4,921)	(5,706)

125

The amoO mor1_1 1 Tf -0.025 0 T7 ((4,921)339T1_0 1 Tf 7.087 0 Td ((5,706)298T1_0

D ... , ... B0.9 ... , ... B1.0 ... .

4.1.9 Credit Impairment Losses

D ... , ... B16.1 ... (... 30, 2019: B10.7 ...), ... 3.5% ... (... 30, 2019: 2.8%). A ... 30, 2020 ... D ... 31, 2019, ... B30.3 ... B21.4 ... 8.6% ... 7.1% ... .

4.1.10 Non-Operating Income (Expenses) and Other Gains

...

4.1.11 Income Tax Expense

D ... , ... B10.5 (... 30, 2019: B7.1), ... 47.5% ... 2019. F ... 30, 2019, ... 26.7% 13.5%, ... B ... 2019, ... , ...

4.2 Financial Position

4.2.1 Inventory

A ... 30, 2020, ... B33.9 (D ... 31, 2019: B23.6), ... : ( ) ... B31.3 (D ... 31, 2019: B21.0); ( ) ... B2.6 (D ... 31, 2019: B2.6), ... 2701, 2806, 2807 ... 2808 ... k B C ... E ... C ... . :

C ...	... 2701, 2806, 2807 ... 2808 ... k B ... C ... E ... C ...
A ...	... E ... C ..., C ..., C ..., ... , C
...	75%
(A ...) (...)	19.3
(A ...) (...)	325.73
...	C ..., ...
...	C ...
C ...	... 30, 2017

4.2.2 Accounts Receivables

A 30, 2020, B352.6 (D 31, 2019: B310.5), B322.5 , 14.5% D 31, 2019, 2019, .

D , , 133 (30, 2019: 146).

4.2.3 Other Receivables and Prepayments

A 30, 2020, B88.4 (D 31, 2019: B68.7).

4.2.4 Investment Properties

A 30, 2020, B107.1 (D 31, 2019: B110.9), k B C E C (302, 303 304) II k B C E C (2/F 11/F) . D , . :

	k B C E C (302, 303 304)
A	E C , C , C , C
	75%
(A .) (. .)	1,959.41
(A .) (. .)	6,766,36
	-

	29, 2043,
	k B C E C (2/F 11/F)
A	E C , C C , C
	75%
(A .) (. .)	6,602.26
(A .) (. .)	11,850.34
	C ,
	29, 2043,

4.2.5 Other Non-current Financial Assets

A 30, 2020, B51.3 (D 31, 2019: B51.3). D , .

4.2.6 Right-of-use Assets

A 30, 2020, B253.4 (D 31, 2019: B235.3), C .

4.2.7 Accounts Payables

A 30, 2020, B63.6 (D 31, 2019: B75.6).

4.2.8 Contract Liability

A 30, 2020, B10.8 (D 31, 2019: B8.6).

4.2.9 Other Payables

A 30, 2020, B93.5 (D 31, 2019: B133.3).

4.3 Liquidity and Capital Resources

:

	For the six months ended June 30,	
	2020	2019
	(RMB'000)	*(B'000)*
	(Unaudited)	*( )*
	17,799	4,157
	(76,436)	(75,880)
/( )	**94,945**	(25,941)
/( )	**36,424**	(98,423)

4.3.1 Net Cash Generated from Operating Activities

D , B17.8 , B28.9 , B16.1 B60.0 , k B90.9 . B14.5 .

4.3.2 Net Cash Used in Investing Activities

D , B76.4 , B67.1 , , , & C .

4.3.3 Net Cash Generated from Financing Activities

D , , k B94.9 B163.5 B39.1 .

4.3.4 Significant Investment, Acquisition and Disposal

30, 2020.

4.4 Indebtedness

4.4.1 Bank Borrowings

A 30, 2020, k B473.5 (D 31, 2019: B310.0), B201.0 B364.5 .

4.4.2 Contingent Liability

A 30, 2020, .

4.4.3 Asset Pledge

, , , B C E C , C B k C . A 30, 2020, C B k.

4.4.4 Lease Liabilities

. A 30, 2020, - , B24.2 , B186.0 .

4.4.5 Financial Instruments

F , - , , , k , . C k .

4.4.6 Exposure to Fluctuation in Exchange Rates

k D B.

k

F 30, 2020, k. C k ,

4.4.7 Gearing Ratio

A 30, 2020, ( ) 42.2% (D 31, 2019: 40.4%).

4.4.8 Employees and Remuneration Policy

A 30, 2020, 3,136 - (D 31, 2019: 2,845 -). D , ( ) B149.5 (30, 2019: B128.1). B98.2 ( ). ,

C E 2018 C ., ., C 2017 13, 2018 (**2017 AGM**). , C 29, 2018 C 30, 2018.

A 2017 A , 8 B C A 20, 2018, 165 , 1,818,529 .

A 15
B C A 26, 2019,
C , B ,
37 ,
273,161 . A 14
23 ,
180,516 , 0.2391%
C
(B10.47).

Category of personnel	Number of persons granted *(person)*	Number of Shares granted *(Share)*	Number of grant representing total issued share capital of the Company
C	17	142,311	0.1885%
B ,	6	38,204	0.0506%
	23	180,516	0.2391%

C .

(溫州箴言康寧投資管理合夥企業(有限合夥))

k 48 ,

k 48

5 PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES

D , C 899,700 k E , ( ) $15,888,990. D :

Repurchase period	Total number of H Shares repurchased	Price paid per share Highest ($)	Lowest ($)	Total consideration ($)
2020	35,000	17.90	17.80	624,200
A 2020	715,200	18.56	17.70	12,993,510
2020	9,400	16.00	15.80	148,540
2020	140,100	15.30	14.70	2,122,740
	899,700			**15,888,990**

T 13, 2020.

, , C , C .

6 EVENTS AFTER THE REPORTING PERIOD

F 30, 2020 , .

7 REVIEW OF INTERIM RESULTS

T A C 30, 2020, .

T A C - D , . (A C), , - D , . A .

8 INTERIM DIVIDEND

T B 30, 2020 (30, 2019:).

9 COMPLIANCE WITH CG CODE

T C C C .

10 ACCOUNTING STANDARDS

T C C A B E 2017, C (C 622) (**Companies Ordinance**).

11 FINANCIAL REPORT

11.1 Accounting Policies

T A B E B F C (**"Ministry of Finance"**) F 15, 2006.

T A B E . 32 F F .

T 2019. T 2019 .

T .

T C 2016. C .

11.2 Interim Financial Statement

[illegible]

11.2.1 Interim Consolidated Income Statement

([illegible])

	For the six months ended June 30, 2020 (Unaudited)	For the six months ended June 30, 2019 ([illegible])
1. Revenue	**465,150,452**	378,910,291
[illegible]: C[illegible]	**(336,864,754)**	(286,882,183)
[illegible]	**(1,999,246)**	(831,972)
[illegible]	**(3,697,157)**	(4,476,806)
[illegible]	**(54,639,015)**	(52,890,346)
[illegible]	**(2,637,407)**	(2,304,024)
F[illegible]	**(11,846,196)**	(10,198,874)
[illegible]: [illegible]	**(14,086,629)**	(11,068,131)
[illegible]	**2,454,371**	1,925,426
A[illegible]: [illegible]	**5,443,616**	6,567,461
[illegible] ([illegible])/[illegible]	**(923,557)**	23,549,073
[illegible]: [illegible] [illegible]	**(1,019,927)**	(2,525,317)
C[illegible]	**(16,112,650)**	(10,730,916)
[illegible]	**–**	(18,587)

11.2.2 Interim Consolidated Statement of Financial Position

(A [illegible] B [illegible])

ASSETS	**June 30, 2020** **(*Unaudited*)**	D [illegible] 31, 2019 *(A[illegible])*
Current assets		
C [illegible] k [illegible]	**216,156,858**	176,030,550
F[illegible]	**–**	30,000,000
A[illegible]	**352,645,140**	310,520,612
[illegible]	**76,843,282**	63,317,366
A [illegible]	**11,516,259**	5,366,020
[illegible]	**33,858,107**	23,568,236
C[illegible]	**–**	12,688,704
Total current assets	**691,019,646**	621,491,488
Non-current assets		
[illegible]	**51,281,869**	51,281,869
[illegible]	**94,068,266**	89,943,193

LIABILITIES AND SHAREHOLDERS’ EQUITY	**June 30, 2020** ***(Unaudited)***	D 31, 2019 *(A)*
Current liabilities		
	332,500,000	250,000,000
	576,686	
A	**63,565,539**	75,554,960
C	**10,772,528**	8,562,126
E	**23,923,352**	36,063,277
	44,736,621	33,430,060
	93,516,092	133,348,712
C	**66,053,557**	79,741,922
Total current liabilities	**635,644,375**	616,701,057
Non-current liabilities		
	100,500,000	20,000,000
	186,013,332	183,808,151
	580,000	2,260,000
	2,000,000	2,000,000
D	**9,797,371**	9,949,267
D	**25,949,596**	21,124,118
Total non-current liabilities	**324,840,299**	239,141,536
Total liabilities	**960,484,674**	855,842,593
Shareholders’ equity		
	75,500,000	75,500,000
C	**826,376,743**	824,715,445
k	**(37,817,508)**	(21,721,144)
	33,189,321	33,189,321
	289,210,662	252,800,715
Total equity attributable to shareholders of the parent company	**1,186,459,218**	1,164,484,337
	127,964,021	97,024,925
Total shareholders’ equity	**1,314,423,239**	1,261,509,262
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	**2,274,907,913**	2,117,351,855

11.2.3 Interim Consolidated Statements of Cash Flow

(A [illegible] B [illegible])

		For the six months ended June 30, 2020 (Unaudited)	2019 [illegible]
1.	**Cash flows from operating activities**		
	C [illegible]		
	[illegible]	**411,405,749**	337,771,543
	C [illegible]	**8,311,056**	7,188,089
	Sub-total of cash inflows	**419,716,805**	344,959,632
	C [illegible]	**(174,912,876)**	(153,687,796)
	C [illegible]	**(162,022,960)**	(137,201,128)
	[illegible]	**(14,474,391)**	(20,832,826)
	C [illegible]	**(50,507,831)**	(29,080,692)
	Sub-total of cash outflows	**(401,918,058)**	(340,802,442)
	Net cash flows from operating activities	**17,798,747**	4,157,190
2.	**Cash flows from investing activities**		
	C [illegible]	**30,010,000**	447,095
	C [illegible]	**96,370**	[illegible]
	[illegible]	**3,870,905**	[illegible]
	[illegible]	**–**	1,833,758
	C [illegible]	**–**	2,555,426
	Sub-total of cash inflows	**33,977,275**	4,836,279
	C [illegible]	**(67,075,009)**	(63,099,075)
	C [illegible]	**(15,145,000)**	(13,020,000)
	[illegible]	**(25,593,510)**	(1,246,349)
	C [illegible]	**(2,600,000)**	(3,351,048)
	Sub-total of cash outflows	**(110,413,519)**	(80,716,472)
	Net cash flows used in investing activities	**(76,436,244)**	(75,880,193)

		For the six months ended June 30,	
		2020	2019
		(Unaudited)	([illegible])
3.	**Cash flows from financing activities**		
	C [illegible]	**23,361,500**	4,245,000
	[illegible]: C [illegible]	**21,771,500**	4,245,000
	C [illegible]	**367,285,789**	170,000,000
	C [illegible]	**–**	
	Sub-total of cash inflows	**390,647,289**	174,245,000
	C [illegible]	**(201,900,000)**	(146,000,000)
	C [illegible]	**(8,241,036)**	(6,647,896)
	C [illegible]	**(85,561,157)**	(47,538,263)
	Sub-total of cash outflows	**(295,702,193)**	(200,186,159)
	Net cash flows generated from/(used in) financing activities	**94,945,096**	(25,941,159)
4.	**Effect of foreign exchange rate changes on cash and cash equivalents**	**116,743**	(758,597)
5.	**Net increase/(decrease) in cash and cash equivalents**	**36,424,342**	(98,422,759)

11.2.4 *Interim Consolidated Statement of Changes in Shareholders' Equity*

(A B)

	Equity attributable to shareholders of the parent company						
	Share capital	Capital surplus	Less: Treasury stock	Surplus reserve	Retained earnings	Non-controlling interests	Total shareholders' equity
Balance at January 1, 2020	75,500,000	824,715,445	(21,721,144)	33,189,321	252,800,715	97,024,925	1,261,509,262
	-	-	-	-	36,409,947	(7,508,712)	28,901,235
	-	-	-	-	-	21,771,500	21,771,500
	-	3,914,851	(1,590,000)	-	-	-	2,324,851
	-	(2,253,553)	-	-	-	(1,709,223)	(3,962,776)
	-	-	(14,506,364)	-	-	-	(14,506,364)
	-	-	-	-	-	18,385,531	18,385,531
Balance at June 30, 2020 (Unaudited)	75,500,000	826,376,743	(37,817,508)	33,189,321	289,210,662	127,964,021	1,314,423,239

Equity attributable to shareholders of the parent company

B50 0 ct2inatio 2020

Share capital **Capital equity**

Td (75,500,000)Tj 7.206 0 Td (826,376,743)Tj 7.87370 T9,88637,

11.3 Notes to the Interim Financial Statement prepared in accordance with the China Accounting Standard for Business Enterprises

11.3.1 Accounts Receivable

(A B)

	June 30, 2020 *(Unaudited)*	D 31, 2019 *(A)*
	6,750,000	8,250,000
	384,779,056	330,174,215
	391,529,056	338,424,215
:	**(38,883,916)**	(27,903,603)
	352,645,140	310,520,612

T 30, 2020 D 31, 2019 :

	June 30, 2020 *(Unaudited)*	D 31, 2019 *(A)*
1	**307,256,118**	266,932,953
1 2	**54,328,309**	57,988,407
2 3	**24,130,088**	13,089,001
3	**5,814,541**	413,854
	391,529,056	338,424,215

A , .

11.3.2 Accounts Payable

(A B)

30, 2020 D 31, 2019
:

	June 30, 2020 (Unaudited)	D 31, 2019 (A)
3	**54,973,453**	65,881,555
3 6	**5,224,098**	7,479,995
6 1	**2,277,029**	1,381,101
1 2	**578,371**	506,880
2 3	**276,874**	94,816
3	**235,714**	210,613
	63,565,539	75,554,960

11.3.3 Revenue and Cost of Sales

(A B)

	For the six months ended June 30, 2020 (Unaudited)	2019 ( )
	438,885,748	360,209,402
	26,264,704	18,700,889
	465,150,452	378,910,291
C	**323,463,045**	279,933,288
C	**13,401,709**	6,948,895
	336,864,754	286,882,183

Revenue and cost of sales from main operations

(A B)

	For the six months ended June 30, 2020	
	(Unaudited) **Revenue from main operations**	*(Unaudited)* **Cost of sales from main operations**
	101,134,489	**86,044,257**
	337,751,259	**237,418,788**
	438,885,748	**323,463,045**
	F 30, 2019	
	( )	( ) C
	96,629,883	82,628,810
	263,579,519	197,304,478
	360,209,402	279,933,288

11.3.4 Earnings Per Share

(A B)

( ) B

	For the six months ended June 30,	
	2020	2019
	(Unaudited)	*( )*
(B)( )	**36,409,947**	52,064,124
( )( )	**72,769,749**	73,040,000
B (B)	**0.50**	0.71

( ) F 13, 2018, C 2,460,000 D . A D k , *A B E* . *7*, 2,460,000 D C 30, 2020.

F 30, 2020, C 899,700 k , k C .

( ) D

D C . F 30, 2020,

B36,409,947. 73,034,363. B0.50. F 30, 2019, B52,064,124. 73,915,743. B0.70.

11.3.5 *Income Tax Expense*

(A B)

	For the six months ended June 30,	
	2020	2019
	(Unaudited)	
C		
	23,778,834	14,824,769
D	**(13,276,086)**	(7,704,851)
	10,502,748	7,119,918

	For the six months ended June 30,	
	2020	2019
	(Unaudited)	
	39,403,983	52,661,149
25%	**9,850,996**	13,165,287
C		
	579,650	1,158,271
F	**121,674**	119,184
A		
	(490,212)	(431,227)
	–	(318,561)
D		
	440,640	51,944
	–	(6,624,980)
	10,502,748	7,119,918

11.3.6 *Dividends*

30, 2020, B 0 1 .7

12 DEFINITIONS

A C – B

B – B C ., . (北京怡寧醫院有限公司), C A 17, 2015, C -

B – C

C – C C ., . (蒼南康寧醫院有限公司), C 15, 2012, C -

C – C C ., .(長春康林心理醫院有限公司), C F 16, 2016, C -

C – C ., ., k C, B k E (k C : 2120)

C C – C C A 14

D ( )– ( ) C

D ( )– ( ) C B1.00 B k

– C ., . (溫州怡寧老年醫院有限公司), C 2, 2015, - C

– – – C

( )– ( ) C B1.00 B k E

$ D

A C

k E

k E k E

C ., (淮南康寧醫院有限公司), C 22, 2017, C -

C ., (廊坊怡寧醫院有限公司, k C ., (廊坊市怡寧醫院管理有限公司)), C D 2, 2015, C A 2, 2020

C C ., (台州市路橋慈寧醫院有限公司, k C ., (台州市路橋怡寧醫院有限公司)), C D 12, 2016, C -

A C

C C C

C ., (青田康寧醫院有限公司), C A 1, 2011, C -

C ., (衢州怡寧醫院有限公司), C 20, 2015, C -

30, 2020

C ., . (永嘉康寧醫院有限公司), C
D 12, 2012, C

B B
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
C

C
A 28, 2020

A *C* *D* *A* *A* *A* *D* *A* *D* *A*